Efficacy of trimetazidine in patients with recurrent angina: a subgroup analysis of the TRIMPOL II study

Current Medical Research and Opinion
Witold RuzylloM Winter

Abstract

The revascularization procedures become more and more popular to treat coronary artery disease, in many countries. Some patients are free of angina after revascularization, without any documented re-stenosis present with recurrent angina symptoms after a period of time. The aim of this work was to assess the efficacy of trimetazidine in the subpopulation of patients with a history of PTCA or CABG, who were included in the TRIMPOL II study. A subgroup of 94 patients was retrospectively analysed from the TRIMPOL II study, a multicentre, double-blind randomised placebo-controlled trial in 426 patients with stable effort angina. These patients have a history of revascularization for coronary artery disease, and they are still symptomatic after 6 months despite a treatment with metoprolol (50 mg twice daily). They were randomly allocated to receive either trimetazidine (20 mg 3 times daily) or placebo for 12 weeks, on top of the beta-blocker. Exercise test parameters, clinical efficacy and safety were assessed. Results were analysed using the Student test, the Mann-Whitney test or the Shapiro-Wilk test. Compared to placebo, the 12-week treatment with trimetazidine significantly improved: time to 1 mm ST segment depression (385.1 s +...Continue Reading

References

Jul 1, 1992·Circulation·UNKNOWN VA Coronary Artery Bypass Surgery Cooperative Study Group
Aug 1, 1990·Cardiovascular Drugs and Therapy·S Dalla-VoltaA Desideri
Sep 16, 1998·The American Journal of Cardiology·A Desideri, L Celegon
Apr 12, 2001·The New England Journal of Medicine·P W SerruysUNKNOWN Arterial Revascularization Therapies Study Group
May 5, 2001·Expert Opinion on Pharmacotherapy·H R Cross
Apr 2, 2003·Fundamental & Clinical Pharmacology·William C Stanley, Mario Marzilli

❮ Previous
Next ❯

Citations

Dec 25, 2007·Cardiovascular Drugs and Therapy·Fanny VaillantQuadiri Timour
Mar 10, 2006·Current Cardiology Reports·Sonal Jani, Steven R Bergmann
Jan 15, 2014·Journal of Cardiac Failure·José Luis WinterSergio Lavandero
Jan 18, 2008·International Journal of Cardiology·Giuseppe MarazziGiuseppe M C Rosano
Aug 26, 2006·The American Journal of Cardiology·Vicente Bertomeu-GonzalezJuan Carlos Kaski
Jun 1, 2012·European Heart Journal. Acute Cardiovascular Care·Paolo IzzoNatale Daniele Brunetti
Nov 27, 2007·Expert Review of Cardiovascular Therapy·Wei Wang, Gary D Lopaschuk
Jan 7, 2014·American Journal of Therapeutics·Csaba A Dézsi
Apr 11, 2014·Angiology·Konstantinos TsioufisAthanasios Manolis
Nov 29, 2020·Cardiology and Therapy·Maria Glezer, UNKNOWN CHOICE-2 study investigators

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.